TREOSULFAN-BASED REDUCED-INTENSITY CONDITIONING FOR ALLOGENEIC HCT IN OLDER AND HIGHLY COMORBID PATIENTS: A SINGLE-CENTER REAL-WORLD COHORT (EHA 2026) - May 13, 2026 - Abstract #EHA-6977; PB3998; "The conditioning consisted of a combination of treosulfan 10g/m2 /day on days -6 to -4, fludarabine, 30mg/m2 /day on days -6 to -2. Fitness / Comorbidity HCT-CI > 2, n (%) ECOG ≤ 2, n (%) 25 (73.5) 33 (97.1) Diagnosis AML, n (%) MDS, n (%) Other myeloid neoplasms, n (%) 14 (41.2) 13 (38.2) 7 (20.6) Donor type MRD, n (%) MUD 10/10, n (%) MMUD 9/10, n (%) Haploidentical, n (%) 10 (29.4) 14 (41.2) 2 (5.9) 8 (23.5) GVHD prophylaxis ATG + MTX + CNI, n (%) PTCy + MMF + CNI, n (%) Other, n (%) 23 (67.6) 9 (26.5) 2 (5.9) CMV prophylaxis Letermovir, n (%) 14 (41.2) Pre-transplant comorbibidities and health conditions, % % Pulmonary comorbidity, n (%) Hepatic comorbidity, n (%) Neurologic comorbidity, n (%) Age > 60 with comorbidity, n (%) Age > 70, n (%) Second transplant, n (%) Additional secondary reason present, n (%) 9 (26.5) 4 (11.8) 1 (2.9) 10 (29.4) 7 (20.6) 3 (8.8) 13 (38.2) Summary/Conclusion Our retrospective analysis suggests that a..."
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Myelodysplastic Syndrome
|
|
MacArena Castillo Godoy 1; Maria Orviz Garcia 1; Ana María Pilar González Rodríguez 1; Ana Julia Gonzalez Huerta 1; Soledad González Muñiz 1; Pilar Palomo 1; Joud Zanabili1
|